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Background and purpose — A challenge comparing 
outcomes from total hip arthroplasty between countries is 
variation in preoperative characteristics, particularly comor-
bidity. Therefore, we investigated between-country variation 
in comorbidity in patients based on ASA class distribution, 
and determined any variation of ASA class to mortality risk 
between countries.
Patients and methods — All arthroplasty registries col-
lecting ASA class and mortality data in patients with elec-
tive primary THAs performed 2012–2016 were identified. 
Survival analyses of the influence of ASA class on 1-year 
mortality were performed by individual registries, followed 
by meta-analysis of aggregated data.
Results — 6 national registries and 1 US healthcare orga-
nization registry with 418,916 THAs were included. There 
was substantial variation in the proportion of ASA class III/
IV, ranging from 14% in the Netherlands to 39% in Finland. 
Overall, 1-year mortality was 0.93% (95% CI 0.87–1.01) 
and increased from 0.2% in ASA class I to 8.9% in class IV. 
The association between ASA class and mortality measured 
by hazard ratios (HR) was strong in all registries even after 
adjustment for age and sex, which reduced them by half in 
all registries. Combined adjusted HRs were 2.0, 6.1, and 22 
for ASA class II–IV vs. I, respectively. Associations were 
moderately heterogeneous across registries.
In recent years, there has been a growing interest in com-
paring outcomes of total hip arthroplasty (THA) between 
arthroplasty registries, including rates of revisions and com-
plications, and patient-reported benefits of surgery (Paxton et 
al. 2011, McGrory et al. 2016, Hughes et al. 2017, Springer 
et al. 2017, Paxton et al. 2018). Comparing aggregate-level 
registry data internationally allows examination of variation 
in practice and outcomes due to differences in implant use, 
populations, and healthcare system. However, these evalua-
tions also have limitations. Registry populations may sub-
stantially differ in patients’ preoperative characteristics and 
therefore may not be directly comparable when assessing 
outcome. As an example, comorbidity is an important pre-
dictor of outcomes of THA, including perioperative mor-
tality and severe complications (Weaver et al. 2003, Rauh 
Interpretation — We observed large variation in ASA 
class distribution between registries, possibly explained by 
differences in background morbidity and/or international 
variation in access to surgery. The similar, strong mortal-
ity trends by ASA class between countries enhance the rel-
evance of its use as an indicator of comorbidity in interna-
tional registry studies.
2 Acta Orthopaedica 2021; 92 (x): x–x
and Krackow 2004), patient-reported benefits (Judge et al. 
2013, Greene et al. 2015) and the need for revision surgery 
(Hooper et al. 2012, Prokopetz et al. 2012). It is possible that 
there are differences in comorbidity level between patients 
undergoing surgery in different countries because of differ-
ences in population health (e.g. burden of cardiovascular 
disease), in health systems, and in how the former may influ-
ence access to surgery. There are, however, few published 
data on population dissimilarities in pre-existing comorbid-
ity (Franklin et al. 2017). Comparisons of outcome might 
therefore require controlling for the population differences 
in the statistical analysis by stratifying or adjusting for such 
patient characteristics. This requires a consistent approach to 
the definition and the measurement of a possible confounder 
such as comorbidity. 
Comorbidity is a multi-dimensional phenomenon that 
reflects the overall health status of a patient. It is strongly 
associated with mortality in patients undergoing THA and 
is an ideal candidate for adjustment in registry analyses of 
mortality. Several methods to measure comorbidity exist. 
The scoring systems vary in the type and detail of informa-
tion they require (Bjorgul et al. 2010, Inacio et al. 2015). 
The most widely collected comorbidity system by arthro-
plasty registries is the ASA classification system (Lübbeke 
et al. 2018). The simplicity of the score underpins its wide-
spread use, although several studies have shown variability 
among anesthesiologists in assigning ASA score (Ranta et 
al. 1997, Mak et al. 2002, Riley et al. 2014, Sankar et al. 
2014). Differences in ASA class distribution and its associa-
tion with mortality may arise from underlying population 
health variation such as obesity and cardiovascular disease 
prevalence, and differences in access to healthcare/surgery. 
Finally, differences in registry populations (e.g., age and 
sex), independent of comorbidity, are susceptible to modi-
fication of the distribution of ASA class and its association 
with mortality. 
Our objectives are therefore (i) to investigate the extent of 
variation in the distribution of ASA class in patients undergo-
ing THA between arthroplasty registries internationally; (ii) to 
explore how far any variation identified is related to other rou-
tinely collected demographic data, specifically age and sex; 
and (iii) to investigate the consistency between ASA class and 




We conducted an analysis of aggregated data prospectively 
collected from participating arthroplasty registries. The distri-
bution of elective primary THAs by ASA class was compared 
between registries. The influence of ASA class on 1-year mor-
tality after elective primary THA was investigated. 
Patients and data sources
Arthroplasty registries were eligible to take part in this study if 
they were full members of the International Society of Arthro-
plasty Registries and collected data on ASA class of patients. 
To ensure comparability between registries, given the vari-
able start date on which registries collected ASA class, we 
restricted inclusion to cases that were elective primary THAs 
performed within the period January 1, 2012 to December 31, 
2016. THAs for which the indication was trauma or malig-
nancy were excluded. Only the first THA in each patient was 
included. For included cases, the following patient character-
istics were extracted: age, sex, BMI, diagnosis (primary or 
secondary osteoarthritis [OA]), and ASA class. Data on death 
from any cause within 1-year of THA was obtained. 
Statistics
Patient -level analysis was performed by the individual regis-
tries following a standardized protocol. The aggregated data 
from each registry was subsequently analyzed centrally. 
Individual registries analysis
All registries described the distribution of baseline character-
istics using frequencies and proportions. Registries calculated 
the cumulative incidence of mortality at 1 year after index 
THA, both overall and by ASA class, using Kaplan–Meier sur-
vival estimates with 95% confidence intervals (CIs). Patients 
were censored at loss to follow-up or end of 1 year follow-up. 
Registries then investigated the association between ASA class 
and risk of 1 year mortality with Cox proportional hazards 
models (presented as hazard ratios [HRs] with CIs) with ASA 
class I defined as the referent category. The proportionality of 
hazards was checked visually by plotting log–log of survival 
against time. Regression coefficients of the Cox models were 
reported with their variance–covariance matrix. The univari-
able model was accompanied by a multivariable model adjust-
ing for age and sex. We did not anticipate a non-linear effect 
of age or an interaction between age and sex, but as a test 
of these assumptions we did repeat the adjusted analyses, to 
allow for these possibilities in the 3 largest registries: Sweden, 
the Netherlands, and Australia. Complete case analysis was 
used for adjusted models.
Aggregate analysis across registers
Kaplan–Meier tables submitted by each participating registry 
were combined to create a summary life table of mortality up 
to 1 year. For this purpose, effective numbers of at-risk patients 
and estimates of mortality at intervals during follow-up were 
collected from each registry. The conditional mortality esti-
mates from each registry were derived and combined using the 
DerSimonian model with random effects (Combescure et al. 
2014) The summary mortality estimates were obtained by the 
product-limit of the conditional mortality estimates. 
The regression coefficients of the Cox models from the 
individual registries’ analysis, both univariate and multivari-
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ate, were combined also using the DerSimonian model with 
random effects for multivariate analyses (Jackson et al. 2010). 
With DerSimonian and Laird’s model, the logarithms of HRs 
are combined across studies by calculating a weighted aver-
age. The weight of a study depends on the precision of the 
estimated HR: the higher the precision, the higher the weight 
of the study. The advantage is that studies with a larger sample 
size tend to have a larger weight in the meta-analysis. In addi-
tion, the between-studies variability is accounted for in the 
calculation of the weights. The extension of DerSimonian 
and Laird’s model for multivariate analyses has been used 
to account for the correlation between the combined HRs. 
Cochran Q tests and I2 statistics were used to assess the het-
erogeneity across registries as described previously (Higgins 
et al. 2003). I2 values of 25%, 50%, and 75% indicate low, 
moderate, and high levels of heterogeneity, respectively.
Statistical analyses were performed with R 4.0.2 for Windows 
(R Foundation for Statistical Computing, Vienna, Austria). 
The R package mvmeta (v1.0.3) (Gasparrini et al. 2012) was 
used to combine logarithm of hazard ratios and the R package 
MetaSurv (v0.3) (Combescure et al. 2014) to combine mor-
tality curves. The 2-sided statistical threshold for significance 
was 0.05.
Ethics, funding, and potential conflicts of interest 
As this was a study of anonymized aggregated data, with no 
individual patient data passed to the researchers, there were 
no ethical issues and consent was not necessary. All data col-
lection and analysis was funded by the core funding to the 
authors’ institutions and organizations.
The authors have no conflicts of interest to declare 
Results 
International variation
7 registries were included in the study. 6 were national and 
population-based (Australia, Finland, Netherlands, New Zea-
land, Norway, and Sweden) and 1 was from a healthcare orga-
nization (Kaiser Permanente, USA). 
The baseline demographic data varied by registry (Table 1). 
The proportion of women ranged from 53% in Australia to 
66% in the Netherlands. Only 9% of patients were aged under 
55 years in the Netherlands compared with 30% in Kaiser Per-
manente. The proportion of obese patients (BMI ≥ 30) ranged 
from 25% in the Netherlands and Sweden to 40% in Austra-
lia, Kaiser Permanente, and New Zealand. The proportion of 
THAs performed for primary OA ranged from 81% in Norway 
to 95% in Kaiser Permanente.
Substantial variation in the proportion in each ASA class 
was observed (Table 2). The Netherlands and Sweden had the 
lowest proportions of ASA class III–IV (14% and 17% respec-
tively), while Australia, Finland, and Kaiser Permanente had 
twice those proportions (34%, 39%, and 35% respectively).
Over all registries, the percentage of patients aged under 55 
years decreased with ASA class (from 27% in ASA class I to 
4.1% in ASA class IV) and the percentage of patients 85 years 
or older increased (from 0.7% in ASA class I to 17% in ASA 
Table 1. Patient demographics by registry. Values are count (%) unless otherwise specified
    Kaiser
Factor Australia Finland Permanente Netherlands New Zealand Norway Sweden
Age category       
 < 55 15,306 (13) 2,726 (12) 13,176 (30) 10,866 (9.2) 6,304 (16) 3,750 (13) 7,025 (11)
 55–64 27,580 (24) 5,356 (24) 15,485 (35) 24,960 (21) 10,510 (27) 6,930 (23) 14,273 (22)
 65–74 39,978 (35) 8,214 (37) 7,704 (18) 44,703 (38) 13,054 (34) 11,008 (37) 25,228 (38)
 75–84 25,907 (23) 5,318 (24) 6,018 (14) 32,657 (28) 7,429 (19) 6,877 (23) 16,447 (25)
  ≥ 85 5,610 (4.9) 801 (3.6) 1,355 (3.1) 5,150 (4.4) 1,165 (3.0) 1,274 (4.3) 2,742 (4.2)
 Missing 0  0  33  155  0  0  0 
Age, mean (SD) 67 (12) 67 (11) 66 (11) 69 (12) 67 (11) 68 (11) 68 (11)
BMI category       
   < 18.5 475 (0.9) 118 (0.6) 351 (0.8) 603 (0.8) 222 (0.8) ND 491 (0.8)
   18.5–24.9 11,384 (22) 5,093 (27) 9,370 (22.3) 24,730 (31) 5,974 (21) ND 19,931 (31)
   25–29.9 19,296 (37) 7,983 (42) 15,318 (36.5) 34,449 (43) 10,748 (38) ND 27,664 (43)
   30–34.9 12,812 (25) 4,353 (23) 10,762 (25.6) 14,920 (19) 6,981 (25) ND 12,275 (19)
   35–39.9 5,350 (10) 1,379 (7.2) 4,893 (11.6) 3,906 (4.9) 3,181 (11) ND 3,173 (4.9)
 ≥ 40 2,636 (5.1) 328 (1.7) 1,327 (3.2) 1,000 (1.3) 1,054 (3.7) ND 570 (0.9)
 Missing 62,428  3,161  1,750  38,883  10,302  ND 1,611 
BMI, mean (SD) 29.4 (6.2) 28.2 (4.8) 29.1 (5.6) 27.4 (4.5) 29.0 (5.6) ND 27.3 (4.4)
Sex       
   Women 60,923 (53) 12,724 (57) 25,148 (57) 77,566 (66) 20,345 (53) 18,961 (64) 37,148 (57)
   Missing 0  10  30  248  0  0  0 
Diagnosis (primary/secondary OA)       
 Primary OA 107,480 (94) 19,336 (90) 41,599 (95) 107,230 (91) 36,080 (94) 24,075 (81) 60,466 (92)
 Missing 0  1,020  0  0  0  87  0 
ND, no data
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class IV) (Figure). Although these broad age patterns were 
observed in all registries, there were substantial differences 
between registries in the actual proportions of patients within 
the same ASA class. The percentage of patients aged under 
55 years in ASA class I ranged from 22% (Netherlands) to 
43% (Finland), and the percentage of patients over 85 years in 
ASA class IV ranged from 10% (Kaiser Permanente) to 20% 
(Australia).  
ASA and mortality within 1 year after THA
Across all registries combined, the overall mortality was 
0.93% (CI 0.87–1.01). This rose with increasing ASA class, 
from 0.18, 0.52, 2.2, to 8.9%, respectively from class I to 
class IV. Although this trend was observed in all individual 
registries (Table 3), ASA class-specific 1-year mortality 
varied. Whereas mortality rates for classes I and II were 
almost identical between registries, there was modest varia-
tion between registries in those in classes III ranging from 
1.3% to 3.1%. Variation was most extensive in class IV 
(range 4.5% to 16%). 
Unadjusted and age- and sex-adjusted HRs for the asso-
ciation between ASA class and 1-year mortality are given in 
Table 4. The pooled unadjusted HR confirmed an increasing 
1-year mortality with increasing ASA class. This rose from an 
HR of 3.2 (CI 2.3–4.3) when comparing ASA class II with I, 
to a substantially higher HR of 59 (38–95) when comparing 
ASA class IV with I. There was moderate heterogeneity in 
the individual registries (I2 around 50%), with lowest HRs in 
Kaiser Permanente and the Netherlands. As an example, the 
unadjusted HRs in Netherlands were half those in Sweden and 
Finland. 
After age and sex adjustment the HRs were lowered by half: 
Table 2. ASA class by registry. Values are count (%)
    Kaiser
Factor Australia Finland Permanente Netherlands New Zealand Norway Sweden Total
ASA class I 11,092 (10) 2,773 (13) 1,390 (3.3) 23,750 (20) 5,972 (16) 4,586 (16) 15,116 (23) 64,679 (15)
ASA class II 57,616 (55) 10,515 (48) 26,634 (62) 77,245 (66) 23,039 (61) 19,319 (65) 38,483 (60) 252,851 (60)
ASA class III 33,969 (33) 8,076 (37) 14,212 (33) 16,586 (14) 8,718 (23) 5,600 (19) 10,793 (17) 97,954 (23)
ASA class IV 1,676 (1.6) 339 (1.6) 499 (1.2) 286 (0.2) 238 (0.6) 111 (0.4) 283 (0.4) 3,432 (0.8)
Any ASA class 104,353  21,703  42,735  117,867  37,967  29,616  64,675  418,916  
Missing  10,028  712  1,036  624  495  223  1,040  14,158 
Total 114,381  22,415  43,771  118,491  38,462  29,839  65,715  433,074 







Age distribution (%) – ASA class I ASA class II ASA class III ASA class IV
< 55      55–46      65–74      75–84      ≥ 85
0 25 50 75 1000 25 50 75 1000 25 50 75 100 0 25 50 75 100
Table 3. 1-year mortality in percentage (95% confidence interval) by registry and 1-year mortality combined across registries
    1-year mortality (%; CI)
  ASA I ASA II ASA III ASA IV All 
Australia  0.10 (0.04–0.16) 0.46 (0.40–0.52) 1.7 (1.5–1.8) 6.8 (5.6–8.0) 0.92 (0.87–0.98)
Finland  0.12 (0.00–0.26) 0.40 (0.27–0.53) 1.9 (1.6–2.2) 7.6 (4.7–11) 1.02 (0.89–1.2)
Kaiser Permanente  0.25 (0.00–0.54) 0.37 (0.29–0.45) 1.3 (1.1–1.5) 4.5 (2.6–6.5) 0.73 (0.64–0.81)
Netherlands  0.30 (0.23–0.37) 0.70 (0.64–0.76) 2.7 (2.5–3.0) 9.4 (5.9–13) 0.92 (0.87–0.98)
New Zealand  0.15 (0.05–0.25) 0.54 (0.45–0.64) 2.6 (2.3–3.0) 13   (9.0–18) 1.04 (0.94–1.1)
Norway  0.15 (0.03–0.28) 0.46 (0.35–0.56) 3.1 (2.6–3.6) 16   (8.0–23) 0.96 (0.84–1.1)
Sweden  0.16 (0.10–0.23) 0.71 (0.63–0.80) 2.5 (2.2–2.8) 8.3 (5.0–12) 0.93 (0.86–1.1)
Combined  0.18 (0.12–0.25) 0.52 (0.43–0.64) 2.2 (1.8–2.7) 8.9 (6.7–12) 0.93 (0.87–1.0)
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both the pooled as well as registry-level HRs. However, not 
all of the effect of ASA on mortality could be captured by 
this adjustment: the increases in the pooled HRs with increas-
ing ASA classes were attenuated but there were still 2.0-fold, 
6.1-fold, and 22-fold (CI as shown) increases in mortality in 
ASA classes II, III, and IV respectively compared with class I. 
Although all registries showed this trend, there was moderate 
heterogeneity across registries, and I2 statistics were around 
50% with flatter rises in Kaiser Permanente and in the Nether-
lands compared with the other registries. As mentioned in the 
methods, we had assumed the effect of age would be linear. 
To test this assumption, we repeated the analysis in the 3 larg-
est registries (Australia, Sweden, and Netherlands) introduc-
ing a non-linear effect of age and an age–sex interaction term. 
Results (not shown) did not modify sensitively the adjusted 
HRs for ASA classes. As these 3 registries represent around 
70% of the patients included in our study we have no reason 
to suspect that these findings are not generalizable to the other 
registries. 
Discussion
First, we have shown there was a large variation in the dis-
tribution of ASA class in patients undergoing THA. Second, 
given the demographic differences between registries, there 
were also differences in age distribution of the registry popu-
lations within ASA classes. The third conclusion relates to the 
association between ASA classes and 1-year mortality. Across 
all registries, worsening ASA class was associated with 
greater 1-year mortality but the magnitude of the unadjusted 
relationship differed between registries. Age and sex adjust-
ment was only able to capture about half to two-thirds of the 
impact of ASA class on mortality, though this was consistent. 
After adjustment a moderate between-registry heterogeneity 
between ASA classes and mortality remained. 
There are a number of methodological issues to consider in 
interpreting these findings, some of which could lead to bias in 
the results. The underlying aim of the study was to investigate 
the extent of variation in comorbidity of patients undergo-
ing THA in different countries. Because ASA class is widely 
accepted as a useful guide to postoperative mortality and com-
plications, and it is the only measure routinely collected by the 
registries, it was used as the proxy for comorbidity (Rauh and 
Krackow 2004, Hackett et al. 2015, Visser et al. 2015). Alloca-
tion of ASA class in clinical practice is subject to inter-rater 
variation, and as such to random error (Sankar et al. 2014). 
This adds noise to comparisons between populations, making 
it more difficult to detect true underlying differences. Despite 
this potential for underestimation of variation, substantial dif-
ferences in ASA class were observed between the populations 
covered by these registries.
There are likely to be between-country differences in scor-
ing, and specifically issues related to local rules about the 
availability of surgery or “upcoding”: at different times and in 
different jurisdictions, there may have been advantages or dis-
advantages for healthcare providers to under- or over-estimate 
the ASA class to support their service. These issues might lead 
to inaccuracies in ASA class allocation, the extent or direction 
of which is unknown. 
There are other methodological issues to consider in inter-
preting these findings. First, there was a modest amount of 
missing data on ASA (< 2% overall), but with completeness 
at 90% or greater in the registries studied it is unlikely to be 
important. There were also minor differences in the number of 
years with available data in the different registries, but not of 
sufficient magnitude to be concerned about secular changes. 
Third, we used meta-analytic approaches, which are com-
Table 4. Meta-analysis of unadjusted and age- and sex-adjusted hazard ratios for the association between ASA classes and 
1-year mortality
  Unadjusted HR (CI) Adjusted HR (CI)
 ASA I as reference ASA II ASA III ASA IV ASA II ASA III ASA IV
Registries         
 Australia 4.5 (2.5–8.2) 17 (9.0–30)   69 (38–129) 2.7 (1.4–4.9) 6.9 (3.8–13) 22 (12–41)
 Finland 3.3 (1.0–11) 16 (5.0–50)   69 (21–229) 2.0 (0.6–6.4) 6.8 (2.1–22) 24 (7.0–84)
 Kaiser Permanente 1.5 (0.5–4.7) 5.3 (1.7–17)   19 (6.0–64) 1.0 (0.3–3.2) 2.7 (0.9–8.4)   7 (2.0–25)
 Netherlands 2.2 (1.7–2.8) 8.8 (6.9–11)   32 (21–50) 1.4 (1.1–1.8) 4.2 (3.2–5.4) 14 (9.0–22)
 New Zealand 3.6 (1.8–7.1) 18 (9.0–34)   97 (47–204) 2.3 (1.2–4.5) 8.0 (4.0–16) 34 (16–74)
 Norway 3.1 (1.3–7.1) 21 (10–48) 120 (47–309) 1.7 (0.7–3.9) 7.7 (3.3–18) 34 (13–91)
 Sweden 4.4 (2.9–6.6) 16 (10–24)   54 (30–95) 3.0 (2.0–4.6) 8.6 (5.6–13) 28 (16–50)
Pooled HR 3.2 (2.3–4.3) 14 (10–19)   59 (38–93) 2.0 (1.4–2.7) 6.1 (4.4–8.5) 22 (15–32)
 P-value a < 0.001 < 0.001   < 0.001 < 0.001 < 0.001 < 0.001
Heterogeneity         
 Q Cochran 11 14 14 12 13 10
 Cochran test (p) 0.06 0.03 0.03 0.06 0.05 0.11
 I2 (%) 50 57 58 51 53 42
 a p-value for testing the null hypothesis that the pooled HR equals 1.
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influence mortality risk, which cannot be easily captured in 
an analysis such as this (Woolhandler and Himmelstein 2017).
There are also a few potential confounders to consider. We 
specifically did not adjust for BMI, given the role of obe-
sity in ASA assignment (Mak et al. 2002). Adjustment for 
BMI could have masked the effect of comorbidity that was 
the underlying aim of the study. There may be other unknown 
confounders that could have been adjusted for, such as socio-
economic status. However, the relationship between socio-
economic status (SES) and ASA grade is complex. There are 
clear associations between SES and multimorbidity (Barnett 
et al. 2012) and it is likely, because of this link, that, after 
adjustment for SES, differences between countries in ASA 
may be attenuated.
In conclusion, there are substantial differences in ASA class 
distribution between the national registries, for which the most 
plausible explanation is between-country differences in the 
underlying health status and healthcare access, as well as in 
scoring. The similar and strong mortality trends by ASA class 
between countries enhances the relevance of the use of ASA class 
as an indicator of comorbidity in international registry studies. 
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